Zynex Inc. (OTCMKTS:ZYXI) – Analysts at Piper Sandler dropped their Q3 2021 earnings per share (EPS) estimates for Zynex in a research note issued to investors on Tuesday, July 28th. Piper Sandler analyst M. O’brien now expects that the company will post earnings of $0.10 per share for the quarter, down from their previous forecast of $0.22. Piper Sandler currently has a “Overweight” rating and a $30.00 target price on the stock. Piper Sandler also issued estimates for Zynex’s FY2021 earnings at $0.60 EPS and FY2022 earnings at $0.81 EPS.
ZYXI has been the subject of a number of other reports. B. Riley upgraded shares of Zynex from a “neutral” rating to a “buy” rating and set a $28.00 target price for the company in a research note on Wednesday. HC Wainwright dropped their price target on shares of Zynex from $30.00 to $25.00 and set a “neutral” rating on the stock in a research report on Wednesday. Finally, Northland Securities reissued a “hold” rating and issued a $22.50 price target on shares of Zynex in a research report on Wednesday. Two analysts have rated the stock with a hold rating and three have given a buy rating to the company’s stock. The stock has a consensus rating of “Buy” and a consensus target price of $23.50.
Shares of Zynex stock opened at $19.12 on Friday. The business’s fifty day moving average price is $23.36 and its two-hundred day moving average price is $16.05. The company has a market capitalization of $663.58 million, a P/E ratio of 86.91 and a beta of 1.05. Zynex has a 1-year low of $7.51 and a 1-year high of $29.73.
Zynex (OTCMKTS:ZYXI) last issued its earnings results on Tuesday, July 28th. The company reported $0.09 EPS for the quarter, hitting the consensus estimate of $0.09. Zynex had a return on equity of 152.81% and a net margin of 33.33%. The company had revenue of $19.26 million during the quarter, compared to analyst estimates of $19.12 million.
Large investors have recently bought and sold shares of the company. BNP Paribas Arbitrage SA raised its stake in shares of Zynex by 121.9% in the first quarter. BNP Paribas Arbitrage SA now owns 4,866 shares of the company’s stock valued at $54,000 after acquiring an additional 2,673 shares during the last quarter. Invesco Ltd. increased its holdings in shares of Zynex by 258.8% in the first quarter. Invesco Ltd. now owns 67,937 shares of the company’s stock valued at $752,000 after purchasing an additional 49,002 shares in the last quarter. Advisor Group Holdings Inc. acquired a new stake in shares of Zynex in the first quarter valued at approximately $617,000. AQR Capital Management LLC increased its holdings in shares of Zynex by 61.2% in the first quarter. AQR Capital Management LLC now owns 79,254 shares of the company’s stock valued at $877,000 after purchasing an additional 30,079 shares in the last quarter. Finally, New York State Teachers Retirement System acquired a new stake in shares of Zynex in the second quarter valued at approximately $1,028,000. Institutional investors own 0.05% of the company’s stock.
In other Zynex news, CFO Daniel J. Moorhead purchased 2,733 shares of the business’s stock in a transaction on Thursday, July 30th. The stock was purchased at an average price of $18.11 per share, for a total transaction of $49,494.63. Following the completion of the purchase, the chief financial officer now directly owns 19,001 shares in the company, valued at $344,108.11. The purchase was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, CEO Thomas Sandgaard sold 1,250,000 shares of the firm’s stock in a transaction dated Tuesday, July 14th. The stock was sold at an average price of $22.00, for a total transaction of $27,500,000.00. The disclosure for this sale can be found here.
Zynex, Inc, a medical technology company, designs, manufactures, and markets electrotherapy medical devices used for pain management and rehabilitation. Its products include NexWave, a dual channel, multi-modality interferential current, transcutaneous electrical nerve stimulation, and neuromuscular electrical stimulation device; NeuroMove, an electromyography triggered electrical stimulation device; and InWave, an electrical stimulation product for the treatment of female urinary incontinence.
Featured Story: What is the significance of a dead cat bounce?
Receive News & Ratings for Zynex Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zynex and related companies with MarketBeat.com's FREE daily email newsletter.